StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a report released on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.
Evogene Trading Down 5.0 %
NASDAQ EVGN opened at $0.63 on Wednesday. The business’s fifty day moving average is $0.79 and its 200 day moving average is $0.74. Evogene has a fifty-two week low of $0.45 and a fifty-two week high of $1.44.
Evogene (NASDAQ:EVGN – Get Free Report) last posted its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. The firm had revenue of $0.58 million for the quarter, compared to the consensus estimate of $1.73 million. Evogene had a negative return on equity of 76.93% and a negative net margin of 423.39%. During the same quarter last year, the company earned ($0.07) earnings per share.
Institutional Trading of Evogene
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Recommended Stories
- Five stocks we like better than Evogene
- Trading Halts Explained
- MarketBeat Week in Review – 4/22 – 4/26
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Most Effectively Use the MarketBeat Earnings Screener
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.